Abstract:Qi Kong, 1 Ling-ling Qian, 1 Lei Zhang, 1 Huan-huan Liu, 1, 2 Fan Yang, 1 Xiao-lu Zhang, 1 Chao Wang, 1 Xiao-xi Zhao, 1 Ku-lin Li, 1 Ru-xing Wang 1, 2 1 Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, People's Republic of China; 2 Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, People's Republic of China Correspondence: Ru-xing Wang; Ku-lin Li, Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, People's Republic of China, Email ; Purpose: The aim of this study was to investigate the effects and mechanisms of SGLT2 inhibitor empagliflozin on diabetic coronary function. Methods: A rat diabetic model was established by injection of streptozotocin. Rats in the treated group were administered empagliflozin by gavage and rat coronary vascular tensions were measured after eight weeks. Large conductance calcium activated K + channel currents were recorded using a patch clamp technique, while human coronary artery smooth muscle cells were used to explore the underlying mechanisms. Results: After incubation with empagliflozin (10, 30, 100, 300, 1000 μmol/L), the Δ relaxation % of rat coronary arteries were 2.459 ± 1.304, 3.251 ± 1.119, 6.946 ± 3.407, 28.36 ± 11.47, 86.90 ± 3.868, respectively. Without and with empagliflozin in the bath solution, BK channel opening probabilities at a membrane potential of +60 mV were 0.0458 ± 0.0517 and 0.3413 ± 0.2047, respectively ( p < 0.05, n = 4 cells). After incubation with iberiotoxin, the Δ tensions of rat coronary arteries in the control (Ctrl), untreated (DM), low empagliflozin (10 mg/kg/d)-treated (DM+L-EMPA) and high empagliflozin (30mg/kg/d)-treated (DM+H-EMPA) group were 103.20 ± 5.85, 40.37 ± 22.12, 99.47 ± 28.51, 78.06 ± 40.98, respectively ( p < 0.01 vs Ctrl, n = 3– 7; p < 0.001 vs DM+L-EMPA, n = 5– 7). Empagliflozin restored high glucose-induced downregulation of Sirt1, Nrf2, and BK-β 1, while the effect of empagliflozin disappeared in the presence of EX-527, a Sirt1 selective inhibitor. Conclusion: Empagliflozin has a vasodilation effect on the coronary arteries in a concentration-dependent manner and can activate BK channels via the Sirt1-Nrf2 mechanism. Keywords: diabetes, SGLT2 inhibitor, vasodilatation, large conductance calcium activated potassium channel Diabetes mellitus (DM), as a chronic non-communicable disease, seriously harms human health. According to the World Health Organization, more than 3 million people worldwide die from diabetes mellitus and related complications each year, mainly from cardiovascular disease (CVD), especially with the most severe coronary vascular lesions. 1 Therefore, exploring the pathogenesis of diabetic coronary function and improving diabetic cardiovascular lesions are of great significance. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are oral hypoglycemic drugs that reduce blood glucose level by inhibiting glucose re-absorption in the renal tubules. Representative drugs of this kind include empagliflozin (EMPA), canagliflozin, dapagliflozin, etc. In addition to glucose control, SGLT2 inhibitors have a wide range of cardiovascular benefits, including improving cardiac energy supply, reducing arterial stiffness, and inhibiting cardiac remodeling effects. 2–4 Recent studies have demonstrated that SGLT2 inhibitor is of great significance in vasodilation, independently of its hypoglycemic effect, which may be associated with K + channels on vascular smooth muscle cells (SMCs). 5,6 Large conductance calcium activated K + (BK) channel consists of four α subunits and four β subunits, 7 widely distributed in all tissues and cells of the human body, especially in vascular SMCs, and is one of the main K + channels on coronary artery SMCs. 8 Our previous study showed that, 9 BK channels regulate coronary artery relaxation, and BK channel function is impaired in diabetes mellitus. In this study, we aimed to examine the vasodilation of empagliflozin and the effect of empagliflozin on BK channels, exploring new mechanisms of the cardiovascular protection of SGLT2 inhibitors and providing a new clinical strategy for the management of cardiovascular complications in diabetes mellitus. Male Sprague Dawley (SD) rats (weight 180 ± 20g) were purchased from Changzhou Carvens Laboratory Animal Co., Ltd. in China. -Abstract Truncated-

The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels

The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps

Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels

The anti-diabetic drug alogliptin induces vasorelaxation via activation of Kv channels and SERCA pumps

Mechanisms underlying the vasodilatory effects of canagliflozin in the rabbit thoracic aorta: Involvement of the SERCA pump and Kv channels

Electrophysiological Effects of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor Dapagliflozin on Human Cardiac Potassium Channels

The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle

The vasodilatory effect of the antidiabetic drug linagliptin via inhibition of Rho-associated protein kinase in aortic smooth muscle

The vasorelaxant effect of antidiabetic drug nateglinide via activation of voltage-dependent K+ channels in aortic smooth muscle

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels

Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway

Potential of dapagliflozin to prevent vascular remodeling in the rat carotid artery following balloon injury

Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells

The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes

Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation